Neuer Therapieansatz bei refraktärer CLL Arzerra® (Ofatumumab): Neuartiger CD20-Antikörper jetzt zugelassen | Zendy

Christoph Kahl | Zendy; Carsten Hirt | Zendy; Susanne Decker | Zendy; Sebastian Rohde | Zendy; Kirsten Jost | Zendy; Inken Hilgendorf | Zendy; Eva Respondek-Dryba | Zendy; Malte Leithäuser | Zendy; Christian Junghanß | Zendy; Mathias Freund | Zendy; Christoph Röllig | Zendy; Monika Nothacker | Zendy; Achim Wöckel | Zendy; Susanne Weinbrenner | Zendy; Manfred Wirth | Zendy; I. Kopp | Zendy; Günter Ollenschläger | Zendy; L. Weißbach | Zendy; Susanne Osanto | Zendy; Hendrik Van Poppel | Zendy; Xiaodong Li | Zendy; Su-Yu Miao | Zendy; Guoliang Wang | Zendy; Yang Li | Zendy; Yongqian Shu | Zendy; Yongmei Yin | Zendy; Michael P. Lux | Zendy; Claudia Reichelt | Zendy; D. Wallwiener | Zendy; R. Kreienberg | Zendy; W. Jonat | Zendy; Michael Gnant | Zendy; Matthias W. Beckmann | Zendy; Falk C. Thiel | Zendy; Annegret Kunitz | Zendy; Stefan Pahl | Zendy; P Podrabský | Zendy; Eva Wardelmann | Zendy; Isrid Sturm | Zendy; Kourong Miao | Zendy; Jianyong Li | Zendy; Hai-rong Qiu | Zendy; Run Zhang | Zendy; Lijuan Chen | Zendy; Hanxin Wu | Zendy; Rong Wang | Zendy; Jianfu Zhang | Zendy; V. PrulièreEscabasse | Zendy; Carlos GomezRoca | Zendy; Estelle Escudier | Zendy; A. Coste | Zendy; Benjamin Besse | Zendy; Christophe Massard | Zendy; JeanCharles Soria | Zendy; Hongfeng Guo | Zendy; Xifeng Qian | Zendy; Juliane Strack | Zendy; Paulo Lopes | Zendy; Manfred Gaspar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Neuer Therapieansatz bei refraktärer CLL Arzerra® (Ofatumumab): Neuartiger CD20-Antikörper jetzt zugelassen

Author(s) -

Christoph Kahl,

Carsten Hirt,

Susanne Decker,

Sebastian Rohde,

Kirsten Jost,

Inken Hilgendorf,

Eva Respondek-Dryba,

Malte Leithäuser,

Christian Junghanß,

Mathias Freund,

Christoph Röllig,

Monika Nothacker,

Achim Wöckel,

Susanne Weinbrenner,

Manfred Wirth,

I. Kopp,

Günter Ollenschläger,

L. Weißbach,

Susanne Osanto,

Hendrik Van Poppel,

Xiaodong Li,

Su-Yu Miao,

Guoliang Wang,

Yang Li,

Yongqian Shu,

Yongmei Yin,

Michael P. Lux,

Claudia Reichelt,

D. Wallwiener,

R. Kreienberg,

W. Jonat,

Michael Gnant,

Matthias W. Beckmann,

Falk C. Thiel,

Annegret Kunitz,

Stefan Pahl,

P Podrabský,

Eva Wardelmann,

Isrid Sturm,

Kourong Miao,

Jianyong Li,

Hai-rong Qiu,

Run Zhang,

Lijuan Chen,

Hanxin Wu,

Rong Wang,

Jianfu Zhang,

V. PrulièreEscabasse,

Carlos GomezRoca,

Estelle Escudier,

A. Coste,

Benjamin Besse,

Christophe Massard,

JeanCharles Soria,

Hongfeng Guo,

Xifeng Qian,

Juliane Strack,

Paulo Lopes,

Manfred Gaspar

Publication year - 2010

Publication title -

onkologie

Language(s) - German

Resource type - Journals

eISSN - 1423-0240

pISSN - 0378-584X

DOI - 10.1159/000318203

Subject(s) - ofatumumab , medicine , cd20 , lymphoma

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore